EDX Medical Group

EDX Medical Group FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of EDX Medical Group (EDX.AQ) as of Nov 2, 2026 is 102.17 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 85.09 % — a change of 20.07% (higher).

FCF Conversion

102.17 %

YoY

20.07%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of EDX Medical Group is 2025 102.17 % . FCF Conversion Rate (FCF/EBITDA) of EDX Medical Group was 2024 85.09 % . It decreases by 20.07% higher compared to the previous year.

The EDX Medical Group FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2021
0.00 GBP
Jan 1, 2022
82.64 GBP
Jan 1, 2023
34.46 GBP
Jan 1, 2024
85.09 GBP
Jan 1, 2025
102.17 GBP
The EDX Medical Group FCF Conversion history
YEARFCF ConversionYoY
102.17 %+20.07%
85.09 %+146.90%
34.46 %-58.29%
82.64 %—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

EDX Medical Group Stock analysis

What does EDX Medical Group do? EDX Medical Group Plc generates revenue through the sale of digitally enabled diagnostic products and services to individuals and organizations. The company offers point-of-care, home, and workplace testing tools that allow personalized diagnosis according to international standards. Its disease surveillance solutions are sold to cross-border agencies and governments for identifying new disease variants with high transmission risks. The firm also partners with researchers and clinicians to commercialize their discoveries into marketable products. The primary buyers of EDX Medical Group's diagnostic tools include healthcare professionals, individuals seeking personal health monitoring, and government agencies responsible for public health surveillance. Cross-border agencies utilize the disease surveillance solutions to track rapidly spreading variants. Researchers and clinicians form strategic partnerships to develop and launch new diagnostic products through the company's platform. EDX Medical Group's product portfolio consists of diagnostic tests for point-of-care, home, and workplace use, alongside disease surveillance systems. The company's services focus on enabling personalized medical diagnosis and early detection of disease variants. Revenue streams are derived from direct sales of diagnostic tools, government contracts for surveillance systems, and partnership agreements with research institutions. EDX Medical Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about EDX Medical Group stock

FCF Conversion Rate (FCF/EBITDA) of EDX Medical Group is 102.17 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of EDX Medical Group changed from 85.09 % to 102.17 %, representing a 20.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) EDX Medical Group since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s EDX Medical Group with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — EDX Medical Group

All Key Metrics — EDX Medical Group